{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:20Z","timestamp":1792099580824,"version":"4.4.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) is considered incurable with the available chemoimmunotherapy approaches, and therefore, newer effective targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors are increasingly used in MCL as chronic suppressive therapy, especially in the elderly. We aimed to describe the treatment patterns in MCL at different lines of therapy with a focus on BTK inhibitor use and compare outcomes with known prognostic factors using a nationwide Flatiron Health electronic health record\u2013derived de-identified database. We analyzed patient-level data from the period of 2011 to 2021. In this study of 4336 patients with MCL, we found that bendamustine plus rituximab chemotherapy was the most commonly used frontline regimen (42%). Maintenance rituximab or consolidative autologous stem cell transplant (ASCT) was administered to 31% of all patients. Also, for patients who received ASCT as consolidation therapy, only 34% subsequently received rituximab maintenance. BTK inhibitors were the most preferred agents in second or later lines of therapy (n = 933, 57%), followed by bortezomib, lenalidomide, and venetoclax, respectively. Among patients treated with BTK inhibitors, the median real-world overall survival (rwOS) was 35 months (95% confidence interval [CI], 27-50), 24 months (95% CI, 22-30), and 18 months (95% CI, 14-21) for first line, second line, and third or later line of therapy, respectively. Patients with a deletion 17p\/TP53 mutation and blastoid variant MCL had poor outcomes; however, BTK inhibitors appeared to mitigate the negative influence of del17p\/TP53-mutated MCL with a hazard ratio of 1.17 (95% CI, 0.88-1.55) on multivariable analysis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007247","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T20:22:43Z","timestamp":1652473363000},"page":"4122-4131","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-0533","authenticated-orcid":false,"given":"Mayur","family":"Narkhede","sequence":"first","affiliation":[{"name":"1Division\u00a0of Hematology and Oncology, Department of Medicine, O\u2019Neal Comprehensive Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[{"name":"1Division\u00a0of Hematology and Oncology, Department of Medicine, O\u2019Neal Comprehensive Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Shea","sequence":"additional","affiliation":[{"name":"1Division\u00a0of Hematology and Oncology, Department of Medicine, O\u2019Neal Comprehensive Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mehta","sequence":"additional","affiliation":[{"name":"1Division\u00a0of Hematology and Oncology, Department of Medicine, O\u2019Neal Comprehensive Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[{"name":"1Division\u00a0of Hematology and Oncology, Department of Medicine, O\u2019Neal Comprehensive Cancer Center, and"},{"name":"2Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"11","key":"2022071815270162300_B1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer."},{"issue":"6","key":"2022071815270162300_B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"issue":"13","key":"2022071815270162300_B3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2022071815270162300_B4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol."},{"issue":"11","key":"2022071815270162300_B5","doi-asserted-by":"crossref","first-page":"911.e1","DOI":"10.1016\/j.jtct.2021.08.014","article-title":"Outcomes and utilization trends of front-line autologous hematopoietic cell transplantation for mantle cell lymphoma","volume":"27","author":"Riedell","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"2022071815270162300_B6","first-page":"153","article-title":"Rituximab maintenance after first-line immunochemotherapy in mantle cell lymphoma: long-term follow-up of the randomized European MCL Elderly Trial","volume":"130","author":"Hoster","year":"2017","journal-title":"Blood."},{"issue":"8","key":"2022071815270162300_B7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol."},{"issue":"10020","key":"2022071815270162300_B8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet."},{"issue":"30","key":"2022071815270162300_B9","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol."},{"issue":"29","key":"2022071815270162300_B10","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022071815270162300_B11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"2022071815270162300_B12","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2001.09765","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020"},{"key":"2022071815270162300_B13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143","article-title":"Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR.","author":"Ma","year":"2020"},{"issue":"2","key":"2022071815270162300_B14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood."},{"issue":"6","key":"2022071815270162300_B15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res."},{"issue":"3","key":"2022071815270162300_B16","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Software."},{"issue":"4","key":"2022071815270162300_B17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer."},{"issue":"17","key":"2022071815270162300_B18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood."},{"issue":"10044","key":"2022071815270162300_B19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet."},{"issue":"6","key":"2022071815270162300_B20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med."},{"issue":"7","key":"2022071815270162300_B21","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood."},{"issue":"11","key":"2022071815270162300_B22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/ajh.26306","article-title":"Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era","volume":"96","author":"Karmali","year":"2021","journal-title":"Am J Hematol."},{"issue":"8","key":"2022071815270162300_B23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia."},{"issue":"3","key":"2022071815270162300_B24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol."},{"issue":"10","key":"2022071815270162300_B25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol."},{"issue":"6","key":"2022071815270162300_B26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Ser Res."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022008993","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4122\/1907521\/advancesadv2022007247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4122\/1907521\/advancesadv2022007247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T15:27:37Z","timestamp":1658158057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4122\/485244\/Evaluating-real-world-treatment-patterns-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007247","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022008993","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}